| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 303.10 +1.01% on 02/27/25 |
Period Open: 306.38
| 335.88 -8.84% on 03/10/25 | -0.20 (-0.07%) since 02/26/25 |
| 3-Month | 257.05 +19.11% on 01/06/25 |
Period Open: 263.18
| 335.88 -8.84% on 03/10/25 | +43.00 (+16.34%) since 12/26/24 |
| 52-Week | 253.30 +20.87% on 12/19/24 |
Period Open: 281.77
| 346.85 -11.73% on 07/25/24 | +24.41 (+8.66%) since 03/26/24 |
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded...
Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame,...
Last week, J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States as the Trump administration considers imposing tariffs...
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry.AMGN Stock PerformanceImage Source: Zacks Investment ResearchAmgen’s stock has been rising consistently,...
Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by putting their money...
It's time for another round of The Market Cap Game Show on Rule Breaker Investing . Remember that market cap calculates a company's value by multiplying share price with shares outstanding, and there's...
/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.
There are exchange-traded funds (ETFs) for just about any investing theme these days. One of the best ...
Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their medicines and...
Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET program that is evaluating the investigational anti-OX40 therapy rocatinlimab...
With volatility spiking and stock market indexes like the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) down on the year, investors may be looking for ways to diversify their portfolios...
It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked three Motley Fool contributors to pick slam-dunk growth stocks investors can...
Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else...
/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
As Gilead Sciences has outperformed its industry peers recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
As Bristol-Myers has outperformed the Dow recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
2 Reasons to Watch AMGN and 1 to Stay Cautious
Amgen has outperformed the healthcare sector over the past year, and analysts are moderately optimistic about the stock’s prospects.
The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype around weight loss drugs isn't new, but when people are losing more than 20%...
/CNW/ -- USA News Group News Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being...
How is the Dow Jones Industrial Average (DJINDICES: ^DJI) performing this year? It might depend on whether you view the proverbial glass of water as half-empty or half-full.
The Dow Jones Industrial Average, which emerged stronger than the other two major indices this year, had its biggest weekly drop since October, losing 2.5%. The slide came amid renewed concerns about economic...
For Immediate ReleaseChicago, IL – February 24, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...
The world’s population is aging at an unprecedented pace. According to WHO’s October 2024 report, the number of people aged 60 and older surpassed children under five for the first time in 2020. By...
J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected fourth-quarter earnings report and an optimistic outlook for the Innovative Medicine segment...
/AMGEN%20Inc_%20HQ%20sign-%20by%20JHVEPhoto%20via%20iStock.jpg)
Amgen stock is an attractive buy on the dip for passive income-focused investors.
Gilead Sciences (GILD) Q4 Earnings: What To Expect
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities....
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to...
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
| 3rd Resistance Point | 323.59 |
| 2nd Resistance Point | 318.91 |
| 1st Resistance Point | 312.88 |
| Last Price | 306.03 |
| 1st Support Level | 302.17 |
| 2nd Support Level | 297.49 |
| 3rd Support Level | 291.46 |
| 52-Week High | 346.85 |
| Fibonacci 61.8% | 311.11 |
| Last Price | 306.03 |
| Fibonacci 50% | 300.08 |
| Fibonacci 38.2% | 289.04 |
| 52-Week Low | 253.30 |
Please check your inbox for a link to activate your My Barchart Account.
If you do not receive the email within a few minutes check your spam folder or contact our support team for assistance.
